Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche notes importance of progression-free survival in breast cancer patients

Roche notes importance of progression-free survival in breast cancer patients

25th February 2008

Roche has commented on the importance of progression-survival to patients with breast cancer, noting the effectiveness of its compound Avastin (bevacizumab) in this regard.

The company reports that breast cancer is the second-most common form of cancer and the second-leading cancer causing death in women, with over 400,000 women dying from the disease each year.

Last week, Roche announced that Genentech has received accelerated approval for Avastin from the US Food and Drug Administration for use in conunction with paclitaxel chemotherapy for the first-line treatment of patients with metastatic locally recurrent breast cancer.

David Miles, medical oncologist at Mount Vernon Hospital in the UK, said: “The decision confirms the importance of progression-free survival as a clinically meaningful benefit to patients.”

He added that Avastin has been shown to effectively doubles the amount of time patients live without any progression in their cancer, which is a significant amount for both those with the disease and their families.

Roche notes that regulators have now recognised that Avastin is a breakthrough drug which can act against breast, lung and colorectal cancer, the three cancers with the highest death toll.

Earlier this month, Roche announced that a phase III clinical trial assessing Avastin in combination with docetaxel chemotherapy as a treatment for metastatic breast cancer had met its primary endpoint.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.